The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.
BRCA
HRD
Parpi
gynecologic oncology
molecular classification
ovarian cancer
target therapies
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
received:
21
09
2024
revised:
11
10
2024
accepted:
16
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
Growing evidence has demonstrated the role of mutations of tumor biomarkers in diagnosing and treating epithelial ovarian cancer. This review aims to analyze recent literature on the correlation between tumor biomarkers and chemotherapy in nonmucinous ovarian cancer, providing suggestions for personalized treatment approaches. An extensive literature search was conducted to identify relevant studies and trials.
Identifiants
pubmed: 39457020
pii: ijms252011239
doi: 10.3390/ijms252011239
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
BRCA1 Protein
0
BRCA2 Protein
0
Poly(ADP-ribose) Polymerase Inhibitors
0
BRCA1 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM